TBS 5

Drug Profile

TBS 5

Alternative Names: Asthma maintenance therapy - Acerus Pharmaceuticals; TBS-5

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Trimel Pharmaceuticals Corporation
  • Developer Acerus Pharmaceuticals Corporation
  • Class Corticosteroids
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 04 Mar 2015 Preclinical development is ongoing in Canada
  • 04 Mar 2015 TBS 5 is available for licensing as of 04 Mar 2015. http://trimelpharmaceuticals.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top